Human plasma carboxylesterase and butyrylcholinesterase enzyme activity: Correlations with SN-38 pharmacokinetics during a prolonged infusion of irinotecan

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 4, 2001, Pages 283-290

  Guemei, A A ^a   Cottrell, J ^a   Band, R ^a   Hehman, H ^a   Prudhomme, M ^a   Pavlov, M V ^a   Grem, J L ^a   Ismail, A S ^a   Bowen, D ^a   Taylor, R E ^a   Takimoto, C H ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Butyrylcholinesterase; Carboxylesterase; Irinotecan; SN 38

Indexed keywords

4 NITROPHENYL ACETATE; 4-NITROPHENYL ACETATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BUTYRYLTHIOCHOLINE; CAMPTOTHECIN; CARBOXYLESTERASE; CHOLINESTERASE; DRUG DERIVATIVE; IRINOTECAN; NITROPHENOL; ACETIC ACID DERIVATIVE; DRUG METABOLITE;

AREA UNDER THE CURVE; ARTICLE; BLOOD; CHEMISTRY; CLINICAL TRIAL; HUMAN; HYDROLYSIS; PHASE 1 CLINICAL TRIAL; PREDICTION AND FORECASTING; ADULT; AGED; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG HYDROLYSIS; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; IN VITRO STUDY; MALE; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BUTYRYLCHOLINESTERASE; BUTYRYLTHIOCHOLINE; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; HUMANS; HYDROLYSIS; NITROPHENOLS; PREDICTIVE VALUE OF TESTS;

EID: 0034743368     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000258     Document Type: Article

References (28)

1. The camptothecins
2. Phase I and pharmacokinetic trial of weekly CPT-11
3. Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms
4. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
5. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
6. CPT-11 converting enzyme from rat serum: Purification and some properties
7. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
8. Possible physiological roles of carboxylic ester hydrolases
9. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
10. Interindividual variation in carboxylesterase levels in human liver microsomes
11. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer
12. 5-Fluoropyrimidines
13. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
14. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
15. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
16. Reaction of a microsomal esterase from hogliver with diethyl rho-nitrophenyl phosphate
17. Colorimetric determination of serum cholinesterase and its genetic variants by the propionylthiocholine-dithiobis(nitrobenzoic acid) procedure
18. Species variation in the specificity of cholinesterases in human and rat blood samples
19. Noncompartmental pharmacokinetic analysis
20. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model
21. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues
22. Decrease of serum paraoxonase activity in chronic renal failure
23. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation
24. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
25. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
26. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A
27. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
28. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism